Introduction
Esophageal Squamous Cell Carcinoma (ESCC) is a highly aggressive malignancy characterized by early metastasis and a poor five-year survival rate of approximately 30%. While transcriptional changes are well-documented, the role of post-transcriptional regulators—specifically RNA-binding proteins (RBPs)—in driving ESCC progression is less understood. IGF2BP1 (Insulin-like growth factor 2 mRNA-binding protein 1) is an oncofetal protein typically active during development but silenced in adults. Its aberrant "re-awakening" in various cancers suggests a potent role in oncogenesis. This study investigates how IGF2BP1 orchestrates the invasive phenotype of ESCC by regulating the stability and translation of specific target mRNAs.
Methods
The researchers employed a multi-disciplinary approach to elucidate the role of IGF2BP1:
- Clinical Validation: Protein and mRNA levels were assessed in 311 ESCC patient samples using immunohistochemistry (IHC) and RNA in situ hybridization (RISH), supplemented by data from The Cancer Genome Atlas (TCGA-ESCA).
- Functional Assays: CRISPR/Cas9 and siRNA-mediated knockdown, alongside plasmid-based overexpression, were used in ESCC cell lines (KYSE30, TE1) to evaluate migration, invasion, and in vivo metastasis in mouse models.
- Mechanistic Discovery: RNA Immunoprecipitation sequencing (RIP-seq) identified direct mRNA targets, while mass spectrometry (Co-IP MS) identified protein partners. RNA stability was measured via Actinomycin D assays, and promoter methylation was analyzed using methylation-specific PCR (MSP-PCR).
Results
IGF2BP1 Overexpression and Clinical Correlation
IGF2BP1 was found to be highly expressed in 49.8% of ESCC tissues, while remaining virtually undetectable in adjacent normal esophageal tissue. High expression levels significantly correlated with the depth of tumor invasion ($P = 0.024$), identifying IGF2BP1 as a potential biomarker for aggressive disease. Functional assays demonstrated that silencing IGF2BP1 markedly reduced the migratory and invasive capabilities of ESCC cells and significantly inhibited lung metastasis in vivo.
The IGF2BP1-INHBA Axis and $m^6A$ Recognition
RIP-seq identified INHBA (Inhibin Beta A) as a primary downstream target of IGF2BP1. IGF2BP1 acts as a "reader" for $m^6A$ (N6-methyladenosine) modifications on INHBA mRNA. By binding to these sites, IGF2BP1 protects INHBA mRNA from degradation, increasing its half-life from 3.6 to 4.7 hours in KYSE30 cells. Furthermore, the study revealed that IGF2BP1 recruits G3BP1 (G3BP stress granule assembly factor 1) to form a complex that enhances the translation efficiency of INHBA, leading to significantly higher protein levels.
Activation of Smad2/3 Signaling
The upregulation of INHBA protein activates the TGF-β/Smad2/3 signaling pathway, promoting the epithelial-mesenchymal transition (EMT) necessary for metastasis. Silencing the IGF2BP1-INHBA axis or using the small molecule inhibitor BTYNB effectively suppressed Smad2/3 activation and attenuated the malignant phenotypes of ESCC cells.
Epigenetic Drivers of IGF2BP1 Expression
The study also addressed the cause of IGF2BP1 overexpression. Methylation-specific PCR indicated that the IGF2BP1 promoter region is frequently hypomethylated in ESCC cells compared to normal cells. This loss of chemical silencing marks allows for the aberrant re-expression of this fetal protein in the adult esophageal environment.
Conclusion
This research identifies IGF2BP1 as a master post-transcriptional regulator in ESCC. By stabilizing INHBA mRNA and enhancing its translation through a partnership with G3BP1, IGF2BP1 drives the Smad2/3-mediated invasive program. These findings highlight the IGF2BP1/INHBA/Smad axis as a promising therapeutic target for patients with aggressive ESCC.
Summary updated